Similarly, a somatic pituitary tumor-associated mutation in the extracellular domain of the GH receptor (GHR) disrupts N-terminal glycosylation of the receptor, thereby impairing GHR trafficking to the membrane, limiting ligand binding, and disrupting auto-feedback inhibition through diminished STAT activation [35]–[36]. Here, SOAT1 is linked to pituitary tumor.